Overview

Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008

Status:
Completed

Trial end date:
2020-06-05

Target enrollment:
0

Participant gender:
All

Summary

The objective of the study is to provide long term access to bosutinib treatment and assess long term safety, tolerability and duration of clinical benefit, without any formal hypothesis testing; therefore, there is no formal primary endpoint.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Pfizer

Criteria

Inclusion Criteria:

- Only subjects previously participating in two specific studies are eligible to enroll
into this study. Enrollment is not open to subjects if not previously enrolled in
studies B1871006 or B1871008.

Exclusion Criteria:

- All subjects are excluded unless previously participating in studies B1871006 or
B1871008.